Hospital de Dona Estefânia is a public Central Hospital serving the Greater Lisbon area as part of the Central Lisbon University Hospital Centre, a state-owned enterprise.

During the past decade, Centro Hospitalar Lisboa Central- Hospital Dona Estefânia conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro Hospitalar Lisboa Central- Hospital Dona Estefânia" #1 sponsor was "Boehringer Ingelheim" with 2 trials, followed by "Celgene" with 2 trials sponsored, "Takeda" with 2 trials sponsored, "Agios Pharmaceuticals, Inc." with 1 trials sponsored and "Bial - Portela C S.A." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Hospitalar Lisboa Central- Hospital Dona Estefânia" #1 collaborator was "Ovid Therapeutics Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Centro Hospitalar Lisboa Central- Hospital Dona Estefânia" are "Eosinophilic Esophagitis" (2 trials), "Epilepsy" (2 trials), "Lung Diseases, Interstitial" (2 trials), "Analgesia" (1 trials) and "Dravet Syndrome" (1 trials). Many other conditions were trialed in "Centro Hospitalar Lisboa Central- Hospital Dona Estefânia" in a lesser frequency.

Most popular intervention types in "Centro Hospitalar Lisboa Central- Hospital Dona Estefânia" are "Drug" (7 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "CC-93538" (2 trials), "Eslicarbazepine acetate" (1 trials), "Eslicarbazepine acetate (BIA 2-093)" (1 trials) and "Nintedanib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro Hospitalar Lisboa Central- Hospital Dona Estefânia" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Centro Hospitalar Lisboa Central- Hospital Dona Estefânia". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Centro Hospitalar Lisboa Central- Hospital Dona Estefânia, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centro Hospitalar Lisboa Central- Hospital Dona Estefânia, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".